Skip To Main Content
Barnabas G Williams on Muck Rack

Barnabas G Williams

As seen in: Nature, BioRxiv, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barnabas G

Contact Barnabas G, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protection

|
By Barnabas G Williams, Jordan R. Barrett, Josefin Bartholdson Scott, Cassandra A Rigby, Matteo Cagiada, Doris Quinkert, Kirsty McHugh, Anna Huhn, Sean A. Burnap, Camille Gourjault, Francesca Byrne, Ana Rodrigues, Laura Bergamaschi, Simon Watson, Noah W. Miller, Lloyd D.W. King, Francesca R Donnellan, Camilla A. Gladstone, Sarah Silk, Jo Salkeld, Angela M Minassian, Katherine Skinner, Weston Struwe, Charlotte M. Deane, Stephen T. Reece, Andrew Ward, Simon Draper, Beatrice Balzarotti, Jemima Paterson, Stefania Scalabrino
| Cell Press Verified
Keywords malaria monoclonal antibodies RIPR vaccines Plasmodium falciparum mAb blood stage Introduction Malaria disease, caused by the parasite Plasmodium falciparum, is a global health problem with an estimated 282 million cases in 2024.1 The WHO currently recommends two malaria vaccines, RTS/S/AS01 and R21/Matrix-M2; however, both vaccines target the same pre-erythrocytic sporozoite stage of the parasite life cycle.
Open in Who Shared Issue with article?

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex - Nature Communications

|
By Barnabas G Williams, Doris Quinkert, Robert J. Ragotte, Lea Barfod, Alexander Douglas, Randall S. MacGill, Kazutoyo Miura, Carole Long, Matthew Higgins, Amelia M. Lias, Cecilia Carnrot, Amy R. Noe, Hannah Davies
| Nature Verified
Abstract Reticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) and RH5-interacting protein (RIPR) to form an essential heterotrimeric “RCR-complex”. We investigate whether RCR-complex vaccination can improve upon RH5 alone.
Open in Who Shared Issue with article?

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex

|
By David Pulido, Barnabas G Williams, Lloyd D.W King, Doris Quinker
| BioRxiv
Abstract In recent years, reticulocyte-binding protein homologue 5 (RH5) has emerged as a leading blood-stage Plasmodium falciparum malaria vaccine antigen. The most advanced blood-stage vaccine candidate in a Phase 2b clinical trial, RH5.1/Matrix-M[TM], is based on a full-length soluble protein-with-adjuvant formulation. RH5 interacts with cysteine-rich protective antigen (CyRPA) and RH5-interacting protein (RIPR) to form an essential heterotrimeric RCR-complex.
Open in Who Shared Issue with article?
See all 3 articles